AssetMark’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BBIO
AssetMark's BBIO Position: Q3 2026 in Review
AssetMark increased its BridgeBio Pharma (BBIO) stake by 27% in Q3 2026, buying an estimated $513K and bringing the position to 30,640 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #953.
AssetMark first reported a position in BBIO in Q3 2023 and has held it in 13 quarters since. 348 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.
- AssetMark held 30,640 shares of BridgeBio Pharma worth $2.02M as of Q3 2026.
- AssetMark bought 6,584 BridgeBio Pharma shares in Q3 2026, an estimated $513K.
- BridgeBio Pharma made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #953 holding.
- AssetMark first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 13 quarters since.
- 348 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.